


OY-201

Cat. No.:	HY-149253
CAS No.:	2962943-05-9
Molecular Formula:	C ₂₅ H ₃₃ Cl ₂ N
Molecular Weight:	418.44
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	OY-201 is a potential and BBB-penetrated anti-ischemic stroke agent. OY-201 shows the good safety and neuroprotective activity in both in vitro and in vivo models ^[1] .	
In Vivo	OY-201 (10-20 mg/kg, IP) attenuates brain injury of MCAO mice, and shows superior safety compared with sertraline ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Male C57BL/6J mice (Middle cerebral artery occlusion (MACO)-induced brain infarction model) ^[1]
	Dosage:	10 mg/kg and 20 mg/kg
	Administration:	IP
	Result:	Attenuated brain injury of MCAO mice. 10 mg/kg of compound OY-201 reduced the infarcted volume to 13.3% and decreased the neurological severity scores to 1.5. Moreover, treatment with a higher dose of compound OY-201 (20 mg/kg) did not further improve the results, which showed an almost equivalent protective effect. OY-201 at 20 mg/kg significantly ameliorated the mortality of MCAO mice (35.7%) and the survival rate of compound OY-201 was 100% at the dose of 10 mg/kg.

REFERENCES

[1]. Chen X, et al. Development of sertraline analogues as potential anti-ischemic stroke agents. Eur J Med Chem. 2023 Apr 5;252:115273.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA